Literature DB >> 11790293

Microvascular angiogenesis and the renin-angiotensin system.

Andrew S Greene1, Sandra L Amaral.   

Abstract

The renin-angiotensin system is one of the major regulatory mechanisms essential for maintaining cardiovascular homeostasis. Angiotensin II is a multifunctional hormone that plays a key role in regulating this system. The importance of the renin-angiotensin system in controlling sodium homeostasis and vascular resistance is well established, however, in the past decade, much attention has been focused on the importance of angiotensin II as a regulator of microvessel density, acting through the AT1 and AT2 receptors. In this review, we discuss the connections between the renin-angiotensin system and other growth factor pathways known to be involved in pathologic and physiologic angiogenesis and rarefaction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790293     DOI: 10.1007/s11906-002-0054-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  42 in total

Review 1.  Localization and function of angiotensin AT1 receptors.

Authors:  A M Allen; J Zhuo; F A Mendelsohn
Journal:  Am J Hypertens       Date:  2000-01       Impact factor: 2.689

2.  Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis.

Authors:  R D Machado; R A Santos; S P Andrade
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-04       Impact factor: 3.619

3.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Authors:  O V Volpert; W F Ward; M W Lingen; L Chesler; D B Solt; M D Johnson; A Molteni; P J Polverini; N P Bouck
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.

Authors:  H Yoshiji; S Kuriyama; M Kawata; J Yoshii; Y Ikenaka; R Noguchi; T Nakatani; H Tsujinoue; H Fukui
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

5.  Microvascular rarefaction and tissue vascular resistance in hypertension.

Authors:  A S Greene; P J Tonellato; J Lui; J H Lombard; A W Cowley
Journal:  Am J Physiol       Date:  1989-01

6.  Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF.

Authors:  S L Amaral; J R Linderman; M M Morse; A S Greene
Journal:  Microcirculation       Date:  2001-02       Impact factor: 2.628

7.  Retinal neovascularization is prevented by blockade of the renin-angiotensin system.

Authors:  C J Moravski; D J Kelly; M E Cooper; R E Gilbert; J F Bertram; S Shahinfar; S L Skinner; J L Wilkinson-Berka
Journal:  Hypertension       Date:  2000-12       Impact factor: 10.190

8.  Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training.

Authors:  S L Amaral; P E Papanek; A S Greene
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

9.  Hemodynamic and microcirculatory changes during development of renal hypertension.

Authors:  I Hernandez; A S Greene
Journal:  Am J Physiol       Date:  1995-01

10.  Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells.

Authors:  B Williams; A Q Baker; B Gallacher; D Lodwick
Journal:  Hypertension       Date:  1995-05       Impact factor: 10.190

View more
  9 in total

1.  The effects of angiotensin peptides and angiotensin receptor antagonists on the cell growth and angiogenic activity of GH3 lactosomatotroph cells in vitro.

Authors:  Dorota Ptasinska-Wnuk; Slawomir A Mucha; Hanna Lawnicka; Jolanta Fryczak; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Endocrine       Date:  2012-03-23       Impact factor: 3.633

2.  Genome-wide map of proximity linkage to renin proximal promoter in rat.

Authors:  Timothy J Stodola; Pengyuan Liu; Yong Liu; Andrew K Vallejos; Aron M Geurts; Andrew S Greene; Mingyu Liang
Journal:  Physiol Genomics       Date:  2018-03-09       Impact factor: 3.107

Review 3.  Inhibition of angiogenesis: a new function for angiotensinogen and des(angiotensin I)angiotensinogen.

Authors:  Pierre Corvol; Noel Lamandé; Amauri Cruz; Jerome Celerier; Jean-Marie Gasc
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

4.  Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.

Authors:  Krishnan Bhaskaran; Ian Douglas; Stephen Evans; Tjeerd van Staa; Liam Smeeth
Journal:  BMJ       Date:  2012-04-24

5.  Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta analysis.

Authors:  Xia Chen; Chang-Hong Yi; Kuang-Guan Ya
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Jul-Sep       Impact factor: 1.636

6.  Integrating Pharmacokinetics Study, Network Analysis, and Experimental Validation to Uncover the Mechanism of Qiliqiangxin Capsule Against Chronic Heart Failure.

Authors:  Yu Zhang; Mingdan Zhu; Fugeng Zhang; Shaoqiang Zhang; Wuxun Du; Xuefeng Xiao
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

7.  Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer.

Authors:  Milad Hashemzehi; Farzad Rahmani; Mahdieh Khoshakhlagh; Amir Avan; Fereshteh Asgharzadeh; Farnaz Barneh; Reyhaneh Moradi-Marjaneh; Atena Soleimani; Hamid Fiuji; Gordon A Ferns; Mikhail Ryzhikov; Mohieddin Jafari; Majid Khazaei; Seyed Mahdi Hassanian
Journal:  EXCLI J       Date:  2021-03-01       Impact factor: 4.068

8.  Effects of Antihypertensive Drugs Use on Risk and Prognosis of Colorectal Cancer: A Meta-Analysis of 37 Observational Studies.

Authors:  Yujiao Deng; Yuxiu Xie; Meng Wang; Peng Xu; Bajin Wei; Na Li; Ying Wu; Si Yang; Linghui Zhou; Qian Hao; Lijuan Lyu; Dai Zhang; Zhijun Dai
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

Review 9.  Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity.

Authors:  Uwe Querfeld; Robert H Mak; Axel Radlach Pries
Journal:  Clin Sci (Lond)       Date:  2020-06-26       Impact factor: 6.124

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.